$ cat ./records/funded-new-polio-vaccine-development-through-who-to-accelerate-er-2005.txt
Funded new polio vaccine development through WHO to accelerate eradication in remaining endemic regions
[RECORD.TXT] · cat --full
The Gates Foundation funded new polio vaccine development through the WHO's Eastern Mediterranean office to accelerate eradication in the remaining endemic regions of South Asia and the Middle East, where the standard oral polio vaccine faced reduced efficacy due to high gut-pathogen competition and inadequate sanitation. The funding supported development and testing of new formulations and delivery strategies for the final eradication push in Pakistan, Afghanistan, and northern India.
Source: https://www.gatesfoundation.org/our-work/programs/global-development/polio
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation total assets surpass $29 billion — the largest private charitable foundation in history
Next →
Formally launched the Water, Sanitation and Hygiene (WASH) initiative as a dedicated Gates Foundation program
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.